gliptin and glp-1 Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus GLP-1 | Summary

This is one of the most common questions we hear

Therefore, while the blood pressurelowering effects seen with GLP-1 therapy are not dramatic, they are biologically consistent and clinically meaningful when considered as part of a broader cardiometabolic strategy

Most current studies focus on preclinical models or specific populations, such as those with type 2 diabetes, which may not be representative of the broader population of women suffering from endometriosis

Other proposed mechanisms include potential effects on cardiac ion channels and alterations in baroreceptor sensitivity , though these remain speculative in humans